R-DXd

Phase 2Biologic

Merck & Co.

R-DXd is one of 130 biologic programs targeting Fallopian Tube Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

129

Competitors

Pipeline

Status by Indication[3][1]

Indication

Fallopian Tube CancerActive, not recruiting

Lung NeoplasmRecruiting

Non-Small Cell Lung CancerActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Solid CancerRecruiting

Fallopian Tube CancerPhase 2/Phase 3

Active, not recruiting

Lung NeoplasmPhase 2

Recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

Solid CancerPreclinical

Recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

R-DXd

Merck & Co.

Phase 2

3 2

PORTRAZZA

Eli Lilly

Preclinical

8 3

Lenvima

Eisai

Preclinical

6 4

Imjudo

AstraZeneca

Preclinical

5 5

Vizimpro

Pfizer

Preclinical

4 6

Ofev

Boehringer Ingelheim

Preclinical

7 7

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 8

Remeron

OOrganon and Co

Preclinical

1 9

Vidaza

Bristol-Myers Squibb

Preclinical

1 10

REGN2810

Regeneron

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1/2Recruiting

Small Cell Lung Cancer

NCT04938817

Q2 2030

PreclinicalRecruiting

Solid Cancer

NCT06161025

Q1 2032

Phase 2Recruiting

Lung Neoplasm

NCT06780098

Clinical

Trials by Indication[1]

Small Cell Lung Cancer1 trial

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT04938817·110 enrolled

Lung Neoplasm1 trial

KEYMAKER-U01 Substudy 01I: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06780098·144 enrolled

Solid Cancer1 trial

A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Preclinical·NCT06161025·860 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for R-DXd. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — R-DXd compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for R-DXd. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

R-DXd

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Q2 2030

Q1 2032

Trials by Indication[1]

Small Cell Lung Cancer1 trial

Lung Neoplasm1 trial

Solid Cancer1 trial

References

Drug Info

Quick Facts

Related News